文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

癌症患者中基于胱抑素C与基于血清肌酐的估算肾小球滤过率不一致与药物相关不良事件

Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论癌症患者中,eGFRcys较eGFRcr低超过30%者,万古霉素超治疗浓度和30天死亡风险更高;作者认为需前瞻性研究优化给药。

这项队列研究纳入美国波士顿2家学术癌症中心的1869例成人癌症患者,基线为同一天测量肌酐和胱抑素C的日期(2010年5月至2022年1月)。主要暴露为eGFR不一致,即eGFRcys较eGFRcr低超过30%;主要结局为基线后90天内药物相关不良事件(万古霉素谷浓度>30 μg/mL、甲氧苄啶-磺胺甲噁唑相关高钾血症>5.5 mEq/L、巴氯芬毒性反应、地高辛水平>2.0 ng/mL)。543例(29%)存在eGFR不一致;该组万古霉素>30 μg/mL发生43/179(24%)vs 7/77(9%),P=0.01,校正OR 2.59(95%CI 1.08-7.03;P=0.04);甲氧苄啶-磺胺甲噁唑相关高钾血症29/129(22%)vs 11/92(12%),P=0.07;巴氯芬毒性反应5/19(26%)vs 0/11,P=0.19;地高辛>2.0 ng/mL 7/24(29%)vs 0/10,P=0.08;30天死亡校正HR 1.98(95%CI 1.26-3.11;P=0.003)。作者认为未来需前瞻性研究以改善癌症患者GFR估算和药物剂量个体化。

要点

  • 癌症患者中eGFRcys较eGFRcr低超过30%者占29%(543/1869),该组万古霉素谷浓度>30 μg/mL发生24%(43/179)vs 9%(7/77)(P=0.01),校正OR 2.59(95%CI 1.08-7.03;P=0.04)。
  • eGFR不一致组甲氧苄啶-磺胺甲噁唑相关高钾血症(>5.5 mEq/L)发生22%(29/129)vs 12%(11/92)(P=0.07),未达统计学显著。
  • eGFR不一致组巴氯芬毒性反应发生26%(5/19)vs 0%(0/11)(P=0.19),地高辛>2.0 ng/mL发生29%(7/24)vs 0%(0/10)(P=0.08),均未达统计学显著。
  • eGFRcys较eGFRcr低超过30%者30天死亡风险升高:校正HR 1.98(95%CI 1.26-3.11;P=0.003)。
  • 作者认为该研究结果提示,对同时评估eGFRcys和eGFRcr的癌症患者,eGFRcys较eGFRcr低超过30%者超治疗药物浓度和药物相关不良事件更常见,需前瞻性研究改善GFR估算和药物剂量个体化。

适用人群与场景

  • 成人癌症患者,来自美国马萨诸塞州波士顿2家主要学术癌症中心,在2010年5月至2022年1月间同一天测量肌酐和胱抑素C;首次同时测量eGFRcr和eGFRcys的日期为基线日期。

诊断标准与关键阈值

  • eGFR不一致定义:eGFRcys较eGFRcr低超过30%。
  • eGFR一致定义:eGFRcys在eGFRcr的30%以内。
  • 主要结局药物相关不良事件阈值:万古霉素谷浓度>30 μg/mL;甲氧苄啶-磺胺甲噁唑相关高钾血症>5.5 mEq/L;巴氯芬毒性反应;地高辛水平>2.0 ng/mL。

研究设计与关键结果

  • 研究类型:队列研究;样本量:1869例成人癌症患者(平均[SD]年龄66[14]岁;948例男性[51%]);地点:美国波士顿2家主要学术癌症中心;时间:2010年5月至2022年1月。
  • 暴露:eGFR不一致(eGFRcys较eGFRcr低超过30%)者543例(29%)。
  • 主要结局(基线后90天内药物相关不良事件):万古霉素谷浓度>30 μg/mL发生43/179(24%)vs 7/77(9%),P=0.01;甲氧苄啶-磺胺甲噁唑相关高钾血症(>5.5 mEq/L)发生29/129(22%)vs 11/92(12%),P=0.07;巴氯芬毒性反应发生5/19(26%)vs 0/11,P=0.19;地高辛水平>2.0 ng/mL发生7/24(29%)vs 0/10,P=0.08。
  • 万古霉素谷浓度>30 μg/mL的校正OR为2.59(95%CI 1.08-7.03;P=0.04)。
  • 次要结局:eGFRcys较eGFRcr低超过30%者30天死亡风险校正HR为1.98(95%CI 1.26-3.11;P=0.003)。

证据类型、等级与局限

  • 证据类型:队列研究;原文未报告证据等级。
  • 局限:原文未报告局限性;作者在结论中提出未来需前瞻性研究以改善和个体化癌症患者的GFR估算与药物剂量。

对床旁实践的改变

  • 作者认为,对同时评估eGFRcys和eGFRcr的癌症患者,eGFRcys较eGFRcr低超过30%者超治疗药物浓度和药物相关不良事件更常见,未来需前瞻性研究以改善和个体化GFR估算与药物剂量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Serum creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate the glomerular filtration rate (GFR) in patients with cancer. Cystatin C-based eGFR (eGFRcys) is an alternative marker of GFR.

OBJECTIVE: To determine whether the therapeutic drug levels and adverse events (AEs) associated with renally cleared medications were higher in patients with cancer whose eGFRcys was more than 30% lower than their eGFRcr.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed adult patients with cancer at 2 major academic cancer centers in Boston, Massachusetts. These patients had their creatinine and cystatin C measured on the same day between May 2010 and January 2022. The date of the first simultaneous eGFRcr and eGFRcys measurement was considered to be the baseline date.

EXPOSURE: The primary exposure was eGFR discordance, defined as an eGFRcys that was more than 30% lower than the eGFRcr.

MAIN OUTCOMES AND MEASURES: The primary outcome was risk of the following medication-related AEs within 90 days of the baseline date: (1) supratherapeutic vancomycin trough level greater than 30 μg/mL, (2) trimethoprim-sulfamethoxazole-related hyperkalemia (>5.5 mEq/L), (3) baclofen toxic effect, and (4) supratherapeutic digoxin level (>2.0 ng/mL). For the secondary outcome, a multivariable Cox proportional hazards regression model was used to compare 30-day survival of those with vs without eGFR discordance.

RESULTS: A total of 1869 adult patients with cancer (mean [SD] age, 66 [14] years; 948 males [51%]) had simultaneous eGFRcys and eGFRcr measurement. There were 543 patients (29%) with an eGFRcys that was more than 30% lower than their eGFRcr. Patients with an eGFRcys that was more than 30% lower than their eGFRcr were more likely to experience medication-related AEs compared with patients with concordant eGFRs (defined as eGFRcys within 30% of eGFRcr), including vancomycin levels greater than 30 μg/mL (43 of 179 [24%] vs 7 of 77 [9%]; P = .01), trimethoprim-sulfamethoxazole-related hyperkalemia (29 of 129 [22%] vs 11 of 92 [12%]; P = .07), baclofen toxic effects (5 of 19 [26%] vs 0 of 11; P = .19), and supratherapeutic digoxin levels (7 of 24 [29%] vs 0 of 10; P = .08). The adjusted odds ratio for vancomycin levels more than 30 μg/mL was 2.59 (95% CI, 1.08-7.03; P = .04). Patients with an eGFRcys more than 30% lower than their eGFRcr had an increased 30-day mortality (adjusted hazard ratio, 1.98; 95% CI, 1.26-3.11; P = .003).

CONCLUSIONS AND RELEVANCE: Results of this study suggest that among patients with cancer with simultaneous assessment of eGFRcys and eGFRcr, supratherapeutic drug levels and medication-related AEs occurred more commonly in those with an eGFRcys more than 30% lower than their eGFRcr. Future prospective studies are needed to improve and personalize GFR estimation and medication dosing in patients with cancer.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Hanna PE, Wang Q, Strohbehn IA, et al. Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer. JAMA Netw Open. 2023. PMID: 37405775. doi:10.1001/jamanetworkopen.2023.21715

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。